Article date: April 2008
By: Alan X. Pan, Amparo De La Peña, Kwee P. Yeo, Clark Chan, Mei T. Loh, Stephen D. Wise, Bernard L. Silverman, Douglas B. Muchmore, in Volume 65, Issue 4, pages 480-487
What is already known about this subject
Aims
To explore the effects of smoking cessation and acute smoking re‐exposure on the pharmacokinetic (PK) and glucodynamic (GD) profiles of AIR® inhaled insulin (AIR Insulin) with or without nicotine replacement therapy (NRT).
Methods
Nondiabetic smokers (n = 24) with normal pulmonary function completed a two‐phase (four‐period), open‐label, randomized euglycaemic clamp study. During the initial study phase, subjects underwent glucose clamps following AIR Insulin dosing, shortly after smoking, 8–12 h after smoking, or following subcutaneous insulin lispro shortly after smoking. AIR Insulin PK and GD were again assessed during and after a 4‐week smoking‐cessation period with or without NRT. In the last study period, subjects smoked one cigarette shortly before final AIR Insulin dosing and glucose clamp, to study the effect of acute smoking re‐exposure on inhaled insulin PK and GD.
Results
Compared with the preceding active smoking phase, the administration of AIR Insulin in nondiabetic subjects undergoing a 4‐week period of smoking abstinence resulted in a decrease in PK and GD of approximately 25% (P = 0.008 for both), an effect which was greater in subjects using NRT. Following rechallenge with a single cigarette (without NRT), GD response to AIR Insulin increased significantly (P = 0.006) towards precessation levels, relative to smoking abstinence. In subjects using NRT, however, the increase in GD was less pronounced.
Conclusion
Smoking, smoking cessation and acute re‐exposure with a single cigarette are associated with clinically significant alterations in AIR Insulin pharmacokinetics and glucodynamics. AIR Insulin should not be used by smokers or those at risk for recidivism.
DOI: 10.1111/j.1365-2125.2007.03041.x
View this article